Challenges to Hemoglobin A1c As a Therapeutic Target for Type 2 Diabetes Mellitus

Overview

Journal J Gen Fam Med

Specialty Public Health

Date 2019 Jul 18

PMID 31312579

Citations 9

Authors

Masayuki Ikeda

Rumiko Shimazawa

Affiliations

Soon will be listed here.

Abstract

Glycated hemoglobin (HbA1c) is widely accepted as the most reliable measure of long-term glycemia. However, there is disagreement among professional medical societies on a proper glycemic target for long-term benefits in type 2 diabetes (T2D). The use of some glucose-lowering drugs was associated with heart failure despite substantial lowering of HbA1c. The failure of intensive glycemic control to reduce cardiovascular risk in some trials again brought into question the usefulness of HbA1c as a therapeutic target in T2D. In large cardiovascular outcome trials, some newer glucose-lowering drugs were associated with higher risks of heart failure or amputation despite comparable glycemic control between the test and placebo groups. Here, we provide evidence that variation in hemoglobin glycation between individuals is responsible for these inconsistencies. We suggest that further research be conducted in this area and that the findings be applied to clinical trials and practice.

Citing Articles

Prevalence and determinants of poor glycaemic control in individuals aged between 18-60 years, at a regional hospital in KwaZulu-Natal Province, South Africa- a cross sectional study.

Zimu L, Mahomed O Afr Health Sci. 2024; 23(4):339-347.

PMID: 38974271 PMC: 11225451. DOI: 10.4314/ahs.v23i4.36.

Comparative Analysis of Biomarkers in Type 2 Diabetes Patients With and Without Comorbidities: Insights Into the Role of Hypertension and Cardiovascular Disease.

Savvopoulos S, Hatzikirou H, Jelinek H Biomark Insights. 2024; 19:11772719231222111.

PMID: 38707193 PMC: 11069335. DOI: 10.1177/11772719231222111.

Chronic hyperglycemia and intracranial meningiomas.

Oreskovic D, Madero Pohlen A, Cvitkovic I, Alen J, Raguz M, Alvarez-Sala de la Cuadra A BMC Cancer. 2024; 24(1):488.

PMID: 38632533 PMC: 11022447. DOI: 10.1186/s12885-024-12243-4.

Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.

Pulleyblank R, Larsen N Pharmacoecon Open. 2023; 7(4):579-591.

PMID: 37178435 PMC: 10333151. DOI: 10.1007/s41669-023-00416-z.

Impact of glycemic control on biventricular function in patients with type 2 diabetes mellitus: a cardiac magnetic resonance tissue tracking study.

Zhu J, Li W, Chen F, Xie Z, Zhuo K, Huang R Insights Imaging. 2023; 14(1):7.

PMID: 36630007 PMC: 9833026. DOI: 10.1186/s13244-022-01357-7.

References

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Khaw K, Wareham N, Bingham S, Luben R, Welch A, Day N . Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004; 141(6):413-20. DOI: 10.7326/0003-4819-141-6-200409210-00006. View

Herman W . Are There Clinical Implications of Racial Differences in HbA1c? Yes, to Not Consider Can Do Great Harm!. Diabetes Care. 2016; 39(8):1458-61. PMC: 4955925. DOI: 10.2337/dc15-2686. View

Hayward R, Reaven P, Wiitala W, Bahn G, Reda D, Ge L . Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 372(23):2197-206. DOI: 10.1056/NEJMoa1414266. View

Li L, Li S, Deng K, Liu J, Vandvik P, Zhao P . Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016; 352:i610. PMC: 4772781. DOI: 10.1136/bmj.i610. View

Nichols G, Hillier T, Erbey J, Brown J . Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001; 24(9):1614-9. DOI: 10.2337/diacare.24.9.1614. View

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y . Japanese Clinical Practice Guideline for Diabetes 2016. Diabetol Int. 2019; 9(1):1-45. PMC: 6224875. DOI: 10.1007/s13340-018-0345-3. View

Nathan D, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine R . Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008; 31(8):1473-8. PMC: 2742903. DOI: 10.2337/dc08-0545. View

10.

Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati F, Powe N . Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004; 141(6):421-31. DOI: 10.7326/0003-4819-141-6-200409210-00007. View

11.

Hempe J, Liu S, Myers L, McCarter R, Buse J, Fonseca V . The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care. 2015; 38(6):1067-74. PMC: 4439529. DOI: 10.2337/dc14-1844. View

12.

Gerstein H, Miller M, Genuth S, Ismail-Beigi F, Buse J, Goff Jr D . Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011; 364(9):818-28. PMC: 4083508. DOI: 10.1056/NEJMoa1006524. View

13.

Bergenstal R, Gal R, Connor C, Gubitosi-Klug R, Kruger D, Olson B . Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels. Ann Intern Med. 2017; 167(2):95-102. DOI: 10.7326/M16-2596. View

14.

Hernandez D, Espejo-Gil A, Bernal-Lopez M, Mancera-Romero J, Baca-Osorio A, Tinahones F . Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC Nephrol. 2013; 14:151. PMC: 3720537. DOI: 10.1186/1471-2369-14-151. View

15.

Cohen R, Holmes Y, Chenier T, Joiner C . Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care. 2002; 26(1):163-7. DOI: 10.2337/diacare.26.1.163. View

16.

Riddle M, Ambrosius W, Brillon D, Buse J, Byington R, Cohen R . Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010; 33(5):983-90. PMC: 2858202. DOI: 10.2337/dc09-1278. View

17.

. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7):1327-34. PMC: 2699715. DOI: 10.2337/dc09-9033. View

18.

Mortensen H, Christophersen C . Glucosylation of human haemoglobin a in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin A1c. Clin Chim Acta. 1983; 134(3):317-26. DOI: 10.1016/0009-8981(83)90370-4. View

19.

Douros A, DellAniello S, Yu O, Filion K, Azoulay L, Suissa S . Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ. 2018; 362:k2693. PMC: 6050517. DOI: 10.1136/bmj.k2693. View

20.

Qaseem A, Wilt T, Kansagara D, Horwitch C, Barry M, Forciea M . Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018; 168(8):569-576. DOI: 10.7326/M17-0939. View